Kline: Rx-to-OTC switch becoming more selective

PARSIPPANY, N.J. — Companies are being more selective in the Rx-to-OTC switches they pursue, Kline & Company  reported in its latest research, the 13th study in its syndicated series, "Rx-to-OTC Switch Forecasts USA: Next Frontier."



According to Kline, future switches will depend on a combination of market-driven forces and safety, as determined by regulators. These switches will be characterized by the sponsor needing to overcome safety concerns with well-designed and well-executed trials that prove consumers can safely use the medication without the intervention of a healthcare professional.



Outlined in the Kline report, some of the categories with the greatest switch potential include benign prostatic hyperplasia, erectile dysfunction, migraine, overactive bladder and sleeping aids.